Larimar Therapeutics Inc
ZA71
Company Profile
Business description
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Contact
Three Bala Plaza East
Suite 506
Bala CynwydPA19004
USAT: +1 844 511-9056
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
65
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,894.20 | 53.70 | 0.61% |
| CAC 40 | 7,915.36 | 78.13 | -0.98% |
| DAX 40 | 23,409.37 | 181.66 | -0.77% |
| Dow JONES (US) | 47,740.80 | 239.25 | 0.50% |
| FTSE 100 | 10,249.52 | 35.23 | -0.34% |
| HKSE | 25,780.85 | 23.56 | 0.09% |
| NASDAQ | 22,695.95 | 308.27 | 1.38% |
| Nikkei 225 | 53,838.42 | 1,109.70 | 2.10% |
| NZX 50 Index | 13,162.51 | 63.68 | 0.49% |
| S&P 500 | 6,795.99 | 55.97 | 0.83% |
| S&P/ASX 200 | 8,663.20 | 60.90 | 0.71% |
| SSE Composite Index | 4,112.62 | 16.02 | 0.39% |